• LAST PRICE
    16.2650
  • TODAY'S CHANGE (%)
    Trending Down-0.4850 (-2.8955%)
  • Bid / Lots
    16.2500/ 1
  • Ask / Lots
    16.2800/ 3
  • Open / Previous Close
    16.6400 / 16.7500
  • Day Range
    Low 16.0800
    High 16.7850
  • 52 Week Range
    Low 12.9500
    High 25.4700
  • Volume
    250,225
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 16.75
TimeVolumeRCUS
09:32 ET1626116.375
09:34 ET296916.295
09:36 ET70016.18
09:38 ET80016.38
09:39 ET48516.23
09:41 ET20016.285
09:43 ET100016.35
09:45 ET150116.405
09:48 ET110016.32
09:50 ET40116.305
09:52 ET70016.33
09:56 ET80616.235
09:57 ET83416.31
09:59 ET23716.36
10:01 ET40016.37
10:03 ET47216.36
10:06 ET194116.365
10:08 ET234816.4
10:10 ET30016.39
10:12 ET22216.41
10:14 ET30016.425
10:15 ET20016.39
10:17 ET27616.42
10:19 ET71716.385
10:21 ET150016.24
10:26 ET124516.175
10:28 ET10016.175
10:30 ET70016.14
10:32 ET30316.145
10:33 ET36216.166
10:35 ET90016.11
10:37 ET353216.19
10:39 ET30016.22
10:42 ET684216.235
10:44 ET110016.22
10:46 ET40016.2
10:48 ET58816.15
10:50 ET188416.11
10:51 ET20016.11
10:53 ET20016.11
10:55 ET846316.2193
10:57 ET261816.275
11:02 ET68816.26
11:04 ET32916.25
11:06 ET30016.26
11:08 ET10016.29
11:09 ET130016.31
11:11 ET30016.33
11:13 ET1061116.42
11:15 ET611716.43
11:18 ET65816.46
11:20 ET30016.455
11:22 ET110316.44
11:24 ET50916.46
11:26 ET238216.42
11:27 ET90016.38
11:29 ET60016.38
11:31 ET130516.395
11:36 ET20016.43
11:38 ET70516.43
11:40 ET40016.39
11:42 ET90016.405
11:45 ET215516.425
11:47 ET231716.395
11:49 ET30016.385
11:56 ET10016.37
11:58 ET561616.47
12:00 ET284216.465
12:02 ET663316.53
12:03 ET315116.6
12:05 ET200016.585
12:07 ET10016.585
12:09 ET118916.59
12:14 ET99716.53
12:16 ET30016.54
12:18 ET60016.54
12:20 ET181716.49
12:23 ET10016.47
12:25 ET54116.475
12:27 ET20016.46
12:30 ET20016.47
12:32 ET97616.48
12:36 ET137116.445
12:38 ET67116.401
12:39 ET290016.415
12:41 ET61116.385
12:43 ET20016.395
12:45 ET1046116.445
12:48 ET1217416.51
12:50 ET395516.48
12:52 ET115016.45
12:54 ET280016.38
12:56 ET50016.36
12:57 ET40116.35
12:59 ET40016.285
01:01 ET25416.25
01:03 ET30016.25
01:06 ET99816.25
01:08 ET73516.22
01:10 ET37316.19
01:12 ET31516.17
01:14 ET131116.22
01:15 ET10016.2
01:19 ET56616.17
01:24 ET157616.19
01:26 ET200016.2
01:28 ET15516.22
01:30 ET11516.22
01:32 ET49516.195
01:33 ET20016.19
01:35 ET363116.23
01:37 ET1025916.3
01:39 ET143316.3
01:42 ET50516.305
01:44 ET62016.265
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRCUS
Arcus Biosciences Inc
1.5B
-5.2x
---
United StatesVIR
Vir Biotechnology Inc
1.5B
-2.7x
---
United StatesXNCR
Xencor Inc
1.5B
-10.7x
---
United StatesARDX
Ardelyx Inc
1.8B
-26.0x
---
United StatesGYRE
Gyre Therapeutics Inc
1.2B
-6.9x
---
United StatesPRTA
Prothena Corporation PLC
1.2B
-6.2x
---
As of 2024-05-23

Company Information

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Contact Information

Headquarters
3928 Point Eden WayHAYWARD, CA, United States 94545-3719
Phone
510-694-6200
Fax
302-730-1370

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder
Terry Rosen
President, Co-Founder
Juan Jaen
Chief Financial Officer
Robert Goeltz
Chief Operating Officer
Jennifer Jarrett
Chief Accounting Officer
Alexander Azoy

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.5B
Revenue (TTM)
$237.0M
Shares Outstanding
91.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.87
EPS
$-3.10
Book Value
$6.12
P/E Ratio
-5.2x
Price/Sales (TTM)
6.4
Price/Cash Flow (TTM)
---
Operating Margin
-113.92%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.